Abstract:Background: Quinolones are widely prescribed for the treatment or prevention of infectious diseases in children. To gain further insight into quinolone-associated adverse event (AE) in children and better protect pediatric patients, continued surveillance of safety data is essential. The purpose of this study was to characterize the safety profiles of quinolone-associated AEs in children by mining the FDA adverse event reporting system (FAERS). Methods: FAERS reports from quarter 1 of 2004 to quarter 1 of 2022 were included in the study. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify adverse events. Reporting odds ratios (ROR) corresponding 95% confidence intervals (CIs) and information component (IC) along with 95% CIs were calculated to detect drug–AE pairs with higher-than-expected reporting rates within the FAERS from System Organ Classes (SOCs) to Preferred Terms (PTs). Reports were considered as signals if the 95% confidence interval did not contain the null value. Results: After inclusion criteria were applied, a total of 4,704 reports associated with quinolones were considered. Most FAERS reports associated with ciprofloxacin ( N = 2,706) followed by levofloxacin ( N = 1,191), moxifloxacin ( N = 375), oflaxacin ( N = 245) and ozenoxacin ( N = 187). The most common age group was 12–18 years. The median weight was 39.0 kilogram. The adverse effects of quinolones emerging for SOCs primarily included Infections and infestations, gastrointestinal symptoms, blood and lymphatic system disorders, cardiac disorders, nervous system disorders, musculoskeletal and connective tissue disorders and psychiatric disorders. The most frequently AE signals at the PT level were pyrexia ( N = 236), febrile neutropenia ( N = 120), off label use ( N = 48), drug resistance ( N = 18) and cardiac arrest ( N = 22) following the use of ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, and ozenoxacin, respectively. Serious oznoxacin-associated AE signals were found and have not been documented in the package insert. They included cardiac arrest ( N = 22; ROR = 19.83; IC = 3.68), overdose ( N = 21; ROR = 4.98; IC = 2.07), seizure ( N = 16; ROR = 6.01; IC = 2.29), small for dates baby ( N = 9; ROR = 14.7; IC = 3.05), completed suicide ( N = 15, ROR = 18.87; IC = 3.51), asthma ( N = 9; ROR = 6.69; IC = 2.24;) and hypotension ( N = 9; ROR = 3.83; IC = 1.68). Conclusion: This study provided additional evidence with respect to quinolones-related AEs for children. Generally, the findings of this study are compatible with AEs recorded in package inserts. The unexpected signals of ozenoxacin justify active vigilance by clinicians and timely monitoring by pharmacovigilance experts.

Safety Profile of Fluoroquinolones: Analysis of Adverse Drug Reactions in Relation to Consumption Data Using Pharmacovigilance Database in Hebei, China

Association Between the Rate of Fluoroquinolones-Resistant Gram-Negative Bacteria and Antibiotic Consumption from China Based on 145 Tertiary Hospitals Data in 2014

Adverse Drug Reactions Induced by Gatifloxacin:Analysis of 866 Cases During 2003～2006

Psychiatric disorders associated with fluoroquinolones: a pharmacovigilance analysis of the FDA adverse event reporting system database

Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions

Assessing Fluoroquinolone-Associated Aortic Aneurysm And Dissection: Data Mining Of The Public Version Of The Fda Adverse Event Reporting System

[Adverse Drug Reaction and Rational Use of Levofloxacin: a Prospective Study].

Pregnancy related adverse events and congenital disorders associated with fluoroquinolones: A real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)

Comparison of Side Effects of Levofloxacin versus Other Fluoroquinolones

An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency

Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)

Safety analysis of quinolones use in minors-based on the FAERS database

Impact of the US Food and Drug Administration warning regarding increased risk of aortic aneurysms or aortic dissections on fluoroquinolone prescribing trends

Fluoroquinolone use in a rural practice

Regional variation in the potentially inappropriate first-line use of fluoroquinolones in Canada as a key to antibiotic stewardship? A drug utilization review study

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database

Comparision and Analysis on the Safety Issues of Gatifloxacin in Home and Abroad

Association Between Fluoroquinolones and Major Adverse Cardiovascular Events: A Systematic Review

Unveiling the association between fluoroquinolones and aortic diseases using real-world database analysis and pharmacological experiments

Occurrence and Risk Assessment of Fluoroquinolone Residues in Chicken and Pork in China

Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis